POSEIDA THERAPEUTICS, INC.

PSTX NASDAQ
0.0000
0.00%
Opening 09:30 07/22 EDT
Open
--
Prev Close
--
High
--
Low
--
Volume
--
Avg Vol (3M)
--
52 Week High
--
52 Week Low
--
% Turnover
0%
Market Cap
--
1D
5D
1M
3M
1Y
5Y

Related

Webull offers POSEIDA THERAPEUTICS, INC. PSTX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops gene engineering technologies to create therapeutics for patients with unmet medical need. The Company has built a pipeline of autologous and allogeneic chimeric antigen receptor thymus (T) cell product candidates, which is focused on the treatment of hematological malignancies and solid tumors. Its P- bone marrow cell maturation antigen (BCMA)-101 is an autologous chimeric antigen receptor (CAR)-T therapy being developed to treat patients with relapsed or refractory multiple myeloma. P-PSMA-101 is an autologous CAR-T product candidate that enables treatment of patients with castrate-resistant prostate cancer (CRPC). P-BCMA-ALLO1 is an allogeneic CAR-T product candidate using cells derived from a donor as starting material that enables treatment of patients with multiple myeloma from a single manufacturing run.
MORE >

Recently

Name
Price
%Change